Cancer Research Technology Limited

The Institute of Cancer Research: Royal Cancer Hospital

The Institute of Cancer Research

Matthew Garth Lloyd

Swen Hoelder

Kwai Ming Jack Cheung

Benjamin Richard Bellenie

Owen Alexander Davis

Rosemary Huckvale

Gavin Collie

Mirco Meniconi

Alfie Brennan

Hannah Woodward

Paolo Innocenti

Michael K Carter

Ana Varela Rodriguez

Michael Keith Carter

Ana Varela RODRÍGUEZ

The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X, X, R, R, R, Rand Ring A are each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

BCL6 inhibitors

The present invention relates to compounds of Formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: wherein X, X, R, Rand Rare each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated.

Benzimidazolone derived inhibitors of BCL6

The present invention relates to compounds of formula I that function as inhibitors of BCL6 (B-cell lymphoma 6) activity: Formula I wherein X, X, X, R, R, R, Rand Rare each as defined herein. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which BCL6 activity is implicated. 

2-quinolone derived inhibitors of BCL6

Growing community of inventors

London, United Kingdom

Matthew Garth Lloyd